30 closest matches · ranked by relevance
Myeloid Leukemia, Chronic, Accelerated Phase · Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Primary: Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population — 48.0; 47.9 percentage of…
Chronic Myelogenous Leukemia
Primary: Major and Overall Hematologic Response (MaHR and OHR) — 9; 103; 112; 12 participants
Myeloid Leukemia, Chronic, Chronic-Phase
Primary: Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up — 51.8; 49.0 percentage of Participants
Chronic Myeloid Leukemia · Ph+ Acute Lymphoblastic Leukemia
Primary: Percentage of CP-CML Participants With Major Cytogenetic Response (MCyR) — 50.7; 70.3 percentage of participants
Leukemia
Primary: Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. — 3; 2; 1; 1…
Chronic Myeloid Leukemia · Philadelphia-Positive Myeloid Leukemia
Primary: Number of Participants With Major Cytogenetic Response (MCyR) at Week 12 — 36; 14 Participants
Myelogenous Leukemia, Chronic
Primary: Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation — 22.3; 44.3; 42.7 Percentage of participants — p=<0.0001
Chronic Myelogenous Leukemia
Primary: Kaplan-Meier Estimates of Overall Survival (All Randomized Participants) — 98.9; 97.7; 96.0; 93.6 Percentage of participants
Chronic Myeloid Leukemia · Blast Crisis
Primary: Major and Overall Hematologic Response (MaHR and OHR) — 2; 34; 36; 4 Participants
Chronic Myeloid Leukemia
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1 participants
Lymphoblastic Leukemia, Acute
Primary: Rate of Hematological Complete Remission (HCR) Obtained During the BMS Induction Treatment Within Day +85 From the Start of BMS (i.e., Whenever Achieved From the Start…
Chronic Myelogenous Leukemia · Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) · Hypereosinophilic Syndrome
Primary: Number of Participants With Major Cytogenetic Response (MCyR) — 191; 44; 22 Participants
Acute Lymphoblastic Leukemia · BCR-ABL1 Fusion Protein Expression · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Event-free Survival Rate (EFS) — 21.3 Months
Myeloid Leukemia, Chronic
Primary: Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 — 45; 29; 75; 92 percentage of participants
Chronic Myelogenous Leukemia in Chronic Phase
Primary: Number of Participants With Confirmed Complete Molecular Response (CMR) — 34 Participants
Accelerated Phase Chronic Myelogenous Leukemia · Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative · Blastic Phase Chronic Myelogenous Leukemia
Primary: Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical…
Leukemia
Primary: Percentage of Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants With Major Cytogenetic Response (MCyR) — 50.8 Percentage of participants
Chronic Myelogenous Leukemia - Chronic Phase
Primary: Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A and B up to 24 Weeks — 23; 26; 1; 3 Participants
CML in Chronic Phase
Primary: Percentage of Participants With Molecular Response (MR4^0) at 18 Months — 38.3 Percentage of Participants
Chronic Myelogenous Leukemia
Primary: Number of Participants With Major Molecular Response (MMR) Rate at 24 Weeks — 40; 10 Participants — p=0.029
Chronic Myelogenous Leukemia
Primary: Percentage of Participants Who Achieved Major Molecular Response (MMR) During the First 12 Months — 74 Participants
Chronic Myeloid Leukemia
Primary: Percentage of Participants With Complete Cytogenetic Response (CCyR) at Year 1 — 70.0; 68.3 Percentage of Participants — p=0.667
Leukemia
Primary: Major Cytogenetic Response (MCyR) Rate — 89.7 percentage of participants
Chronic Myelogenous Leukemia · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation — 30; 11; 13; 13 participants
Philadelphia Chromosome Positive · Chronic Myelogenous Leukemia in Chronic Phase
Primary: MMR Rate at 12 Mos. of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who…
CML · Chronic Myelogenous Leukemia · Leukemia, Myeloid Chronic
Primary: Molecular Response (MR)^4.5 Rate at 48 Weeks and Difference in Rate Between Asciminib + Imatinib and Imatinib Alone — 19.0; 28.6; 0.0 Percentage of participants
Adult Acute Lymphoblastic Leukemia in Remission
Primary: Disease Free Survival — 1.7 years
Leukemia, Myelogenous, Chronic
Primary: Participants With Complete Molecular Response (Molecular CR) — 23 Participants
Philadelphia Chromosome Positive CML
Primary: Overall Survival — 89.2 percentage of participants
Myeloid Leukemia, Chronic
Primary: Number of Participants With Best Confirmed Complete Cytogenetic Response (cCCyR) Within 12 Months — 204; 177 Participants — p=0.0056